An observational study in Dermatologic Disease, sponsored by Wake Forest University Health Sciences. Recruiting at 1 site in United States. Open to participants aged 10 Years and older. Per ClinicalTrials.gov, last updated 2026-09-28.
Sponsored by Wake Forest University Health Sciences · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 202 studies in Skin Diseases with a site in United States — 32 open to participants now, 49 under way, 9 of them phase 3. Skin Diseases · United States.
Among the 202 studies in Skin Diseases with a site in United States, this one is the 13th largest by planned enrollment of the 28 observational ones that give a count, is one of 15 that started in 2025, is one of 29 observational ones, reaches primary completion later than 28 of the 48 other live ones, and was the 187th registered.
497 studies on the registry are indexed under Skin Diseases; 78 are open to participants now.
Browse Skin Diseases studies →32 of the 202 studies in Skin Diseases with a site in United States are open now. Recruiting first, the newest first:
IAS Skin Care · Sites in United States
Ages 25–65 · Women only · Healthy volunteers
WiQo S.p.A. · Sites in United States
Ages 18+ · Healthy volunteers
Spyre Therapeutics, Inc. · Sites in United States, Canada
Ages 18–75
Pfizer · Sites in United States, Canada, Japan and 1 more country
Ages 12+
Pfizer · Sites in United States, Canada, Japan
Ages 12+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 55 Skin Diseases studies recruiting now, 27 (49%) set no upper age limit and 18 (33%) stop at 75 or younger; 20 take children under 18; 20 take healthy volunteers.
This study: 10 Years and older · all sexes.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
202 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 23 · Phase 2 69 · Phase 3 46 · Phase 4 8
First in 1978; this study’s year is marked. 15 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 400 is above the median of 163 across 102 observational studies indexed under Skin Diseases.
Median enrollment 99 across the 172 interventional studies, 298 across the 28 observational. Of the 142 that completed or were terminated, 90 (63%) have results posted.
This tab as a report to print or save as PDF → With an account.
139 of 202 have an industry lead sponsor. The 10 most frequent:
Wake Forest University Health Sciences is the lead sponsor of 1,353 studies on the registry; 202 are open to participants now.
Of its 332 completed or terminated interventional studies of FDA-regulated products, 251 (76%) have results posted.
Wake Forest University Health Sciences has 2 studies filed under Skin Diseases — fewer than ten, so there is no comparison to draw.
19 of the studies in Skin Diseases with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07144345Phase 3Sun Pharmaceutical Industries, Inc.Study of Reformulated Levulan Kerastick Plus PDT for Actinic Keratosis on Face and Scalp | 2027-01 |
| NCT07144852Phase 3Sun Pharmaceutical Industries, Inc.Study of Reformulated Levulan Kerastick Plus PDT for Actinic Keratosis on Upper Extremities | 2027-01 |
| NCT07717346Krystal Biotech, Inc.A Study to Investigate Safety and Efficacy of KB111 for the Treatment of Hailey-Hailey Disease | 2026-11 |
| NCT06674980C5 BiomedicalClinical Trial Assessing Human Placental Membrane Products and Standard of Care Versus Standard of Care in Nonhealing DFUs and VLUs | 2026-11-22 |
| NCT07866131WiQo S.p.A.Observational Assessment of Skin Appearance Changes During PRX S Cosmetic Treatment in Participants With Acne-Prone Skin | 2026-12 |
Add all 19 to your calendar (.ics) → With an account.
Among the 202 studies in Skin Diseases with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Consented patients will have three images taken of their dermatologic conditions within the Belle.ai software. These images will be uploaded and saved within the Belle software system where a single AI-generated differential list will be generated based on the three photos. All photos uploaded will be de-identified. The software will not have any unique identifiers of participants saved in the system. The photos will be named based on participant enrollment numbers or unique code numbers and no unique identifiers will be attached to the photos. There will be no data collection form necessary for this study
Belle.ai provides a differential diagnosis from more than 2,000 different skin conditions leveraging a database trained on over 500,000 images. The image referencing technology deploys deep learning to analyze an uploaded clinical image and then matches its geometric pattern characteristics to Belle.ai's database of images to provide reference differentials. The purpose is to determine the validity of the Belle.ai software in diagnosing common dermatologic diseases across a range of skin tones.
Consented patients will have three images taken of their dermatologic disease within the Belle.ai software. These images will be uploaded and saved within the Belle system where a single AI-generated differential list will be generated based on the three photos. The study coordinator will review uploaded patient "cases" and assign the cases for review and adjudication to designated Dermatologic Review Committee (DRC) members within the Belle web portal. Successful validation will require >80% concordance between Belle.ai's primary working diagnosis (#1 on the differential) and our dermatology experts. A team of dermatology experts will then secondarily assess the concordance among the remaining diagnoses.
Up to 400 participants will be recruited for this study
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The study, subject recruitment, and analysis will be conducted within the Advocate Health system at Atrium Health Wake Forest Baptist (AHWFB) in Winston-Salem, NC. Recruiters for this study include Advocate Health dermatology attendings, fellows, and staff, who will capture images of patients presenting to Wake Forest Dermatology Clinics in Winston-Salem, NC.
concordance of Belle.ai diagnoses with physician diagnoses.
The study coordinator will review uploaded patient "cases" and assign them for review and adjudication to designated Dermatologic Review Committee (DRC) members within the Belle web portal. The DRC will be comprised of 1-2 Advocate Health board-certified dermatologists from each of the Winston, Charlotte, and Midwest dermatology practices.
Time frame: Day 1
Plan to share: Undecided — The images will be uploaded and saved within the Belle system where a single AI-generated differential list will be generated based on the three photos. The study coordinator will review uploaded patient "cases" and assign the cases for review and adjudication to designated Dermatologic Review Committee (DRC) members within the Belle web portal.
No publications or documents are linked to this record.
Started Sep 2025 (actual). Primary completion is estimated for Sep 2027, 24 months after the start.
Of 54 observational studies under Skin Diseases, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 250. This study's planned 24 months is below that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Wake Forest University Health Sciences →